The PI3Kδ inhibitor idelalisib suppresses liver and lung cellular respiration

Idelalisib (an inhibitor of phosphatidylinositol-3-kinase-delta) is approved for treatment of B-cell malignancies, with a Boxed Warning concerning potentially fatal hepatic, lung, and intestinal toxicities. The mechanisms of these tissue-specific adverse events have yet to be elucidated. This in vit...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Int J Physiol Pathophysiol Pharmacol
Autors principals: Hammadi, Suleiman Al, Almarzooqi, Saeeda, Abdul-Kader, Hidaya Mohammed, Saraswathiamma, Dhanya, Souid, Abdul-Kader
Format: Artigo
Idioma:Inglês
Publicat: e-Century Publishing Corporation 2015
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4697667/
https://ncbi.nlm.nih.gov/pubmed/26823960
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars